Olmesartan Medoxomil for Hypertension: A Clinical Review

P and T

Volumn 27, Issue 12, 2002, Pages 611-618

  Norwood, Daryl ^a,b   Branch III, Evans ^a   Smith, Bridget ^c   Honeywell, Marlon ^a,d  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b Ambulatory Care   (United States)

^c JACKSON MEMORIAL HOSPITAL   (United States)

^d Ambulatory Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; FLUCONAZOLE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; OLMESARTAN; PLACEBO; RIFAMPICIN; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; BINDING AFFINITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG MARKETING; DRUG METABOLISM; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT;

EID: 0347655346     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000;101:1586.
2. Johnstone MT, Perez A, Stewart R, et al. The angiotensin receptor blocker: Candesartan reduces atherosclerosis in a dose-dependent manner [Abstract]. J Am Coll Cardiol 2000;1133.
3. 1 receptor blockade atherosclerosis: Hopeful insights into vascular protection. Circulation 2000;101:1496.
4. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-752.
5. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial-the Losartan Heart Failure Survival Study Elite II. Lancet 2000;355:1582-1587.
6. Watanabe H, Kakihara M. Losartan improves endothelium dependent vasodilation in patients with non-insulin dependent diabetes mellitus [Abstract]. J Am Coll Cardiol 2000;1023.
7. 1 receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Am J Hypertens 1999;34(Pt 2):969.
8. Erdem Y, Usalan C, Haznedaroglu IC, et al. Effects of angiotensin-converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999;12(11, Pt 1):1071.
9. Chung O, Unger T. Angiotensin II receptor blockade and end organ protection. Am J Hypertens 1999;12(Suppl 12) (1-2):150S.
10. Greenbert BH: Role of angiotensin receptor blockers in heart failure not yet resolved. Circulation 1999;100:1032.
11. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994;251:143-150.
12. 1 receptors. Regul Pept 1995;59:303-311.
13. Edwards RM, Aiyar N, Ohlstein EH, et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260(1):175-181.
14. McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 1999;39:547-559.
15. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87(Suppl):37C-43C.
16. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001;41:515-527.
17. 1)-receptor antagonist CS-866 in patients with mild to moderate hypertension [Abstract No. P.11]. J Hum Hypertens 1999;13(Suppl 3):4.
18. Masonson HN, Punzi HA, Neutel JM, et al. CS-866 (angiotensin II receptor antagonist): A double-blind study using ambulatory blood pressure monitoring in hypertensive patients [Abstract No. D035]. Am J Hypertens 1998;11(4 Pt 2):77.
19. Püchler K, Laeis P, Stumpe KO. A comparison of the efficacy and safety of the oral angiotensin II antagonist olmesartan medoxomil with those of atenolol in patients with moderate to severe hypertension under continuous treatment with hydrochlorothiazide [Abstract No. P2.175]. J Hypertens 2001;19(Suppl 2):153.
20. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87(8A):37-43.
21. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-291.
22. Benicar® package insert. Sankyo Pharma, Inc, New York.
23. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-242.
24. Kawaratani T, Laeis P, Püchler K, et al. The effect of an antacid (aluminum magnesium hydroxide) on the pharmacokinetics and safety of the oral angiotensin II antagonist CS-866 in healthy male subjects [Abstract No. 145]. J Hypertens 1999;17(Suppl 3):S243.
25. Püchler K, Laeis P, Kawaratani T, et al. The effect of the combination of the oral angiotensin II antagonist CS-866 and warfarin on pharmacodynamics, pharmacokinetics and safety in healthy male subjects [Abstract No. 271]. J Hypertens 1999;17(Suppl 3):275.
26. Van Mieghem W. A multicentre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension [Abstract No. P2.174]. J Hypertens 2001;19(Suppl 2):152.
27. Williams PA. A multicentre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus captopril in patients with mild to moderate essential hypertension. J Hypertens 2001;19(Suppl 2):300.
28. Ball K. A multicentre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II antagonist olmesartan medoxomil versus losartan in patients with mild to moderate essential hypertension [Abstract No. P2.176]. J Hypertens 2001;19(Suppl 2):153.
29. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-291.
30. Cozaar® package insert. Merck, West Point, PA, 1999.
31. Diovan® package insert. Novartis, East Hanover, NJ, 1998.
32. Avapro® package insert. Bristol-Myers Squibb, Princeton, NJ, 1998.
33. Atacand® package insert. Astra Pharmaceuticals, Wayne, PA, 1998.
34. Micardis® package insert. Boehringer Ingelheim, Ridgefield, CT, 1999.
35. Teveten® package insert. Solvay, Buffalo Grove, IL, 1999.